Literature DB >> 6766310

Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates.

J D Stoeckler, C Cambor, R E Parks.   

Abstract

The kinetic parameters (Km and Vmax) of sugar-modified analogues of inosine and guanosine have been determined with human erythrocytic purine nucleoside phosphorylase (PNP). Steric alterations at the 2' and 3' positions greatly lessened or abolished substrate activity. However, the 5'-deoxy- and 2',5'-dideoxy-beta-D-ribofuranosyl and the alpha-L-lyxosyl analogues were good substrates, indicating that the 5'-hydroxyl and the orientation of the 5'-hydroxy-methyl group are not important for binding. The sugar phosphate analogue, 5-deoxyribose 1-phosphate, was synthesized from 5'-deoxyinosine with immobilized PNP, and its presence was verified by using it in the enzymic synthesis of 5'-deoxyguanosine. The adenosine versions of the 5'-modified analogues were also found to react with adenosine deaminase, albeit at less than 1% of Vmax.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6766310     DOI: 10.1021/bi00542a016

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

1.  Neighboring group participation in the transition state of human purine nucleoside phosphorylase.

Authors:  Andrew S Murkin; Matthew R Birck; Agnes Rinaldo-Matthis; Wuxian Shi; Erika A Taylor; Steven C Almo; Vern L Schramm
Journal:  Biochemistry       Date:  2007-04-04       Impact factor: 3.162

2.  Catalytic site conformations in human PNP by 19F-NMR and crystallography.

Authors:  Javier Suarez; Antti M Haapalainen; Sean M Cahill; Meng-Chiao Ho; Funing Yan; Steven C Almo; Vern L Schramm
Journal:  Chem Biol       Date:  2013-02-21

3.  Design and directed evolution of a dideoxy purine nucleoside phosphorylase.

Authors:  David P Nannemann; Kristian W Kaufmann; Jens Meiler; Brian O Bachmann
Journal:  Protein Eng Des Sel       Date:  2010-06-04       Impact factor: 1.650

Review 4.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

5.  Disposition of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in mice.

Authors:  S M el Dareer; K F Tillery; J R Kalin; D L Hill
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

6.  Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides?

Authors:  M D Johnson; B D Anderson
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

7.  Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats.

Authors:  M G Wientjes; J L Au
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

8.  Ribocation transition state capture and rebound in human purine nucleoside phosphorylase.

Authors:  Mahmoud Ghanem; Andrew S Murkin; Vern L Schramm
Journal:  Chem Biol       Date:  2009-09-25

9.  Remote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase.

Authors:  Suwipa Saen-Oon; Mahmoud Ghanem; Vern L Schramm; Steven D Schwartz
Journal:  Biophys J       Date:  2008-01-30       Impact factor: 4.033

10.  Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs.

Authors:  S Kaul; C A Knupp; K A Dandekar; K A Pittman; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.